UK’s C4X Discovery signs $400m deal with AstraZeneca to develop treatment of respiratory diseases

British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of
inflammatory and respiratory diseases using its NRF2 Activator programme.

The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial,
including $2 million upfront.

In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties
upon commercialisation of any treatment.